Clinical Trials Browser

Phase 1 × Carcinoma, Non-Small-Cell Lung × necitumumab × Clear all

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02789345 2024-02-05

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1 Completed

29 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02451930 2020-10-05

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Phase 1 Completed

71 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02411591 2020-07-09

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

66 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis